secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apellis Pharmaceuticals, Inc. (APLS)
CIK:        0001492422
Form:       8-K
Filed at:   2021-11-17T23:59:59+00:00
Accession:  0001193125-21-331994
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apellis Pharmaceuticals prices $350M public offering of 8.75M shares at $40/share
--------------------------------------------------------------------------------

- Apellis priced public offering of 8.75M shares at $40.00/share for gross proceeds of $350M.
- Underwriters have 30-day option to purchase up to 1.3125M additional shares at the same price less discounts.
- Estimated net proceeds of ~$330.2M, or ~$379.8M if underwriters fully exercise option.
- Offering expected to close Nov. 18, 2021; J.P. Morgan, Goldman Sachs, Evercore are joint book-running managers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492422/000119312521331994/0001193125-21-331994-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492422/000119312521331994/d222547d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-331994

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer